Список проголосовавших за комментарий " Cytokinetics announces preclinical data for CK-2127107 was presented at MDA Scientific Conference; mouse models exhibit 'significant' nerve dysfunction and/or muscle atrophy and a decrease in maximum muscle force production (12.20)<p>In collaboration with Astellas Pharma (<strong>ALPMY</strong>), Cytokinetics is developing CK-2127107 as a potential treatment for people living with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.</p><ul><li>The study evaluated CK-2127107 in 2B/2B-Neo Intermediate SMA mice, in collaboration with Lurie Children's Hospital and Hung Li SMA mice. These mouse models exhibit significant nerve dysfunction and/or muscle atrophy and a decrease in maximum muscle force production. Muscle force production was assessed by electrical stimulation of the sciatic nerve and plantar flexor force was measured in response to a range of stimulation frequencies.</li><li>Single doses of CK-2127107 increased isometric force in situ in response to sub-tetanic nerve stimulation in both mouse models. In the 2B/2B-Neo SMA mice, force output at a physiologically relevant sub-tetanic stimulation frequency was significantly increased following dosing of CK-2127107 at 10 mg/kg and 30 mg/kg. In the Hung Li SMA mice, force output at sub-tetanic nerve stimulation increased with 30 mg/kg of CK-2127107 to levels higher than wild-type control mice. In both the 2B/2B Neo and Hung Li SMA mouse models there was a leftward shift of the force-frequency response curve indicating a calcium sensitizing effect of CK-2127107 in the skeletal muscle of these mouse models of SMA with nerve dysfunction and muscle atrophy. These results suggest that CK-2127107 and other FSTAs may be viable therapeutics for improving muscle function in SMA.</li></ul>"